Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 2 1

Interventions

pembrolizumab 610 Carboplatin 375 Paclitaxel 283 Cisplatin 268 Gemcitabine 256 Pemetrexed 194 Bevacizumab 191 Nivolumab 190 Docetaxel 190 Injections 169 Cyclophosphamide 148 atezolizumab 138 Capecitabine 134 Fluorouracil 133 Oxaliplatin 132 Dexamethasone 129 Fulvestrant 115 durvalumab 114 130-nm albumin-bound paclitaxel 111 fludarabine 102 Cetuximab 101 Leucovorin 97 Rituximab 96 venetoclax 90 Lenalidomide 84 Prednisone 79 enzalutamide 78 Azacitidine 76 Irinotecan 74 Ipilimumab 73

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × HDAC-42 × 1 year × Clear all

NCT05130866 2025-10-07

POPLAR-NF2

Recursion Pharmaceuticals Inc.

Phase 2/3 Terminated

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡